BEVERLY HILLS, Calif., March 30, 2016 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today that it has extended its agreement with Theradex Systems, Inc. ("Theradex"), a leading global Contract Research Organization ("CRO"), to manage the Company's clinical sites in the United States. Through this continued partnership, Theradex will lead the Company in commencing its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients in the United States.
"We selected Theradex to manage our clinical sites in the United States, due to Theradex's invaluable assistance in finalizing the Investigational New Drug Application (IND #124642) with the U.S. FDA for Rich's lead drug RP-323 in patients with AML," said Ben Chang, CEO of Rich Pharmaceuticals. "The expansion of our team, through our collaboration with Theradex, should allow us to advance the RP-323 program as efficiently and quickly as possible to start the clinical trials in the United States."
About Theradex Systems, Inc.:
Theradex Systems, Inc. is an international contract research organization providing complete professional services for the clinical research and development of pharmaceutical compounds, medical devices and diagnostic tests in the areas of oncology and life-threatening diseases. Theradex conducts studies that lead to marketing approval of significant medical advances; and has built a reputation on assuring the scientific objectivity and meticulous quality control that fulfills all regulatory requirements. Theradex's expertise is also available to assist client personnel in expedited development planning and execution. Find out more at www.theradex.com
This press release contains certain "forward-looking statements" which are statements that are not purely historical, and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that they will prove to be accurate. Investors should refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC (at www.sec.gov).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-further-extends-cro-agreement-with-theradex-systems-to-manage-upcoming-phase-12-clinical-trial-for-its-acute-myelocytic-leukemia-aml-and-myelodysplastic-syndrome-mds-drug-in-the-united-states-300243193.html
SOURCE Rich Pharmaceuticals, Inc.